Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by New Age Alpha Advisors LLC

Key Points

• New Age Alpha Advisors LLC reduced its stake in Sarepta Therapeutics by 72.5% in Q1, owning 19,342 shares valued at approximately $1,234,000 after selling 50,998 shares.
• Sarepta Therapeutics reported an earnings per share (EPS) of $2.02 for the last quarter, significantly exceeding analysts' estimates of $0.89 and marking a 68.4% increase in revenue year-over-year.
• As of the latest reports, Sarepta has a consensus rating of "Hold" from analysts, with an average target price of $48.80, indicating a cautious outlook among investors.

New Age Alpha Advisors LLC trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 72.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,342 shares of the biotechnology company's stock after selling 50,998 shares during the period. New Age Alpha Advisors LLC's holdings in Sarepta Therapeutics were worth $1,234,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Capital International Investors boosted its holdings in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after buying an additional 2,437,855 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock worth $348,368,000 after buying an additional 285,100 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Sarepta Therapeutics by 0.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company's stock worth $237,901,000 after buying an additional 10,343 shares during the last quarter. Alkeon Capital Management LLC boosted its holdings in Sarepta Therapeutics by 34.7% in the 4th quarter. Alkeon Capital Management LLC now owns 853,845 shares of the biotechnology company's stock worth $103,819,000 after buying an additional 220,000 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Sarepta Therapeutics by 22.6% in the 4th quarter. Northern Trust Corp now owns 803,511 shares of the biotechnology company's stock worth $97,699,000 after buying an additional 147,874 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $17.96 on Friday. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. The firm has a fifty day moving average price of $22.12 and a 200 day moving average price of $58.00. The company has a market cap of $1.77 billion, a P/E ratio of -20.64 and a beta of 0.46. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $144.22.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million during the quarter, compared to the consensus estimate of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.04%. The company's revenue was up 68.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.07 earnings per share. Sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reissued a "neutral" rating on shares of Sarepta Therapeutics in a research note on Monday, June 16th. BMO Capital Markets raised their target price on shares of Sarepta Therapeutics from $25.00 to $50.00 and gave the stock a "market perform" rating in a research note on Tuesday, July 29th. William Blair reissued an "outperform" rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 29th. Leerink Partnrs lowered shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 18th. Finally, TD Cowen lowered shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 target price on the stock. in a research note on Wednesday, June 18th. Six investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Hold" and an average target price of $48.80.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.